Leaving BNY Website

 

You are leaving the BNY Mellon's Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2025 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
  

To learn more about DRs, please contact DRBrokerSolutions@bny.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Regulation S Disclaimer

 

Access To This Company Profile Is Restricted To Non-U.S. Persons Outside The United States Within The Meaning Of Regulation S Under The U.S. Securities Act Of 1933, As Amended (The "Securities Act").1

 

This company profile does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction or under any circumstances in which such offer or solicitation is unlawful.

 

Each person accessing this company profile, by so doing, will be deemed to have acknowledged that: (1) It is not a U.S. person (within the meaning of Regulation S under the Securities Act) and is located outside the U.S. (within the meaning of Regulation S under the Securities Act); and (2) Any securities described herein (A) have not been and will not be registered under the Securities Act or with any securities regulatory authority of any state or other jurisdiction and (B) may not be offered, sold, pledged or otherwise transferred except to persons outside the U.S. in accordance with Regulation S under the Securities Act pursuant to the terms of such securities.

 

If you agree with and accept the foregoing and the Terms of use governing this site, please select "Accept" below. Otherwise, press "Decline" to return to the previous page.

 

1 As defined in the Securities Act, the term "U.S Person" means: (1) any natural person resident in the United States; (2) any partnership or corporation organized or incorporated under the laws of the United States; (3) any estate of which any executor or administrator is a U.S. person; (4) any trust of which any trustee is a U.S. person; (5) any agency or branch of a foreign entity located in the United States; (6) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (7) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (8) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.

I Accept Decline

© 2024 The Bank of New York Mellon Corporation
Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Back to Daily DR Market Summary

StreetAccount Summary - Europe Pre-Open: FTSE +0.14%, DAX30 +0.11%, CAC40 +0.13%

May 16 ,2025

  • Synopsis

    • Europe indices are set to open mostly higher today with US equities finishing mostly higher in Thursday trading, ending a bit off best levels. Nasdaq closed lower after six straight gains still up 6%+ WTD; other major indices also on pace for solid weekly returns.

    • Asian equities mixed Friday. Hang Seng underperforming with Alibaba leading tech declines. Mainland China weaker. Japan and Korea little changed. Taiwan and Australia outperforming. Japan preliminary GDP showed economy contracted by more than expected in Q1.

    • S&P 500 futures flat afterhours.

    • Friday sees, in central banks, ECB's Cipollone remarks at 9:30CET at meeting of the Euro Cyber Resilience Board for pan-European Financial Infrastructures. SNB's Schlegel speech title 'Trade war and geopolitical upheaval: Monetary policy in times of uncertainty' at 13:00CET at event hosted by Swiss Media Forum. Riksbank's Seim, ECB's Lane, BOE's Lombardelli panellists at 17:00CET at event hosted by The Federal Reserves (Thu-Fri).

    • Economic: France Q1 unemployment rate, Italy Apr final CPI, Mar trade balance, Eurozone Mar trade balance

    • Richemont (CFR.SW) reports FY Operating profit €4.47B vs FactSet €4.57B. Ascelia Pharma (ACE.SS) reports Q1 EPS (SEK0.23) vs FactSet. Aegon (AGN.NA) reports Q1 Operating capital generation (before holding funding & op. exp.) €267M vs consensus €279.0M. Swiss Re (SREN.SW) reports Q1 net income $1.28B vs consensus $938M

  • Politics/Macro/World News

    • Turkish Central Banker Warns of Prolonged Period of High Rates (BBG )

    • UK ministers consider cutting tax-free cash Isa allowance (FT )

  • Top company news

    • Earnings/updates

      • DBK.GR (Deutsche Bank) -- announces application for further share buyback and reconfirms path to 2025 targets

      • MOLN.SW (Molecular Partners) -- reports financial results and highlights from Q1 2025

      • ETL.FP (Eutelsat Communications) -- reports Q3 revenue €300.6M vs consensus €302.0M

      • B4B.GR (METRO) -- reports Q2 EPS (€0.43) vs year-ago (€0.53)

      • UNI.IM (Unipol Gruppo) -- reports Q1 net income €285M vs FactSet €250M [2 est, €245-255M]

      • ODL.NO (Odfjell Drilling) -- reports Q1 EPS $0.13 vs FactSet $0.12 [6 est, $0.08-0.16], raises dividend

      • PHOR.RU (PhosAgro) -- Group increased its production of agrochemicals by 3.6% y/y in 1Q 2025 to a record 3.11M tonnes

      • PHOR.RU (PhosAgro) -- reports Q1 adjusted net income RUB36.73B, +71% vs year-ago RUB21.49B

      • SOLG.LN (SolGold) -- reports Q3 EPS ($0.003) vs year-ago ($0.010)

      • ELN.IM (El.En.) -- reports Q1 net income €16.3M vs year-ago €16.0M

    • M&A

      • EDPR.PL (EDP Renovaveis) -- signs a put option giving right to sell a 121 MW wind portfolio in France and Belgium to Amundi Transition Energétique for ~€0.2B (enterprise value)

      • DLAR.LN (De La Rue) -- PSF Entities no longer intends to make offer for De La Rue

      • ACA.FP (Credit Agricole) -- Crédit Agricole Leasing & Factoring completes acquisition of German group Merca Leasing announced in Oct 2024

      • ATRL.CN (Atkinsrealis Group) -- EU clears AtkinsRéalis' sale of stakes in 407 ETR

      • GFC.FP (Gecina) -- to acquire office complex in Paris Central Business District

      • HELN.SW (Helvetia Holding) -- board approves planned merger of Caser with Helvetia Seguros and Suizo.

      • AUTN.SW (Autoneum Holding) -- acquires Chinese automotive supplier Chengdu FAW-Sihuan Automobile Interior Parts; purchase price around CHF 16M (excluding cash and cash equivalents and debt)

    • Healthcare

      • SAN.FP (Sanofi) -- FDA grants orphan drug designation to rilzabrutinib for sickle cell disease

      • BAYN.GR (Bayer AG) -- Bayer preparing to place Monsanto in bankruptcy if new Roundup settlement fails - media report

      • BAYN.GR (Bayer AG) -- Follow-up Bayer preparing to place Monsanto in bankruptcy if new Roundup settlement fails - Reuters

    • Other

      • RUI.FP (Rubis) -- Chairman Nils Christian Bergene to step down

      • Green Tea starts trading in Hong Kong after 168.4M-share IPO priced at HK$7.19/share

      • Rio Tinto invests $1.2B to modernize century-old hydroelectric power plant in Quebec

  • Key rating changes

    • Upgrades

      • R3NK.GR (Renk Group) -- to overweight from neutral at JPMorgan (timing uncertain)

      • CVC.NA (CVC Capital Parnters) upgraded to overweight from equal-weight at Morgan Stanley

    • Downgrades

      • NIBE.B.SS (NIBE Industrier) -- to hold from buy at Pareto

      • ALV.GR (Allianz) -- downgraded to hold from buy at HSBC

    • Initiations

      • RBT.FP (Robertet) -- neutral at Oddo

  • Data

    • Nikkei (0.07%) to 37729.03

    • Hang Seng (0.62%) to 23308.70

    • Shanghai Composite (0.46%) to 3365.15

    • S&P futures (2.0) vs prior close of 5933.3

    • €-$ +0.0030 or +0.27% to 1.1216

    • $-¥ (0.44) or (0.30%) to 145.25

    • €-¥ (0.08) or (0.05%) to 162.87

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE